IFNB1 and depressive symptom measurement: Improving psychological well-being (treating depression and anxiety), sleep quality improvement, attending cognitive rehabilitation courses, administering disease modifying therapies (DMTs) such as interferon beta (IFNb), natalizumab will impact positively on cognition status of patients with MS (102).